Literature DB >> 26802286

Oncological Characteristics of Radiological Invasive Adenocarcinoma with Additional Ground-Glass Nodules on Initial Thin-Section Computed Tomography: Comparison with Solitary Invasive Adenocarcinoma.

Aritoshi Hattori1, Takeshi Matsunaga1, Kazuya Takamochi1, Shiaki Oh1, Kenji Suzuki2.   

Abstract

INTRODUCTION: We aimed to evaluate the oncological outcomes of radiological invasive adenocarcinoma with additional ground-glass nodules (AGGNs) on initial thin-section computed tomography (CT).
METHODS: We examined 473 patients with surgically resected clinical stage IA lung adenocarcinoma showing a radiological invasive appearance on thin-section CT. Radiological invasiveness was defined as a solid tumor with a consolidation tumor ratio of at least 0.5 but no greater than 1.0 on thin-section CT.
RESULTS: Ninety patients (19%) had dominant invasive adenocarcinoma (DA) with AGGNs, whereas 383 (81%) had solitary invasive adenocarcinoma (SA). DA showed a significantly lower maximum standardized uptake value of (18)F-fluorodeoxyglucose on positron emission tomography (p = 0.0086), higher frequency of radiological part solid tumor (p = 0.0232) and histological lepidic predominant tumor (p = 0.0015), and lesser presence of nodal involvement (p = 0.0350) and lymphovascular invasion (p = 0.0001) than with SA. Surgically resected AGGNs were shown to be pathologically atypical adenomatous hyperplasia in 17% of patients, adenocarcinoma in situ in 53%, and minimally invasive adenocarcinoma in 21%. Furthermore, the 5-year overall survival of DA with AGGNs was better than that of SA, and the difference was significant (92.2% versus 79.9%, p = 0.0323). On the basis of a multivariate analysis, tumor size, maximum standardized uptake value, and consolidation status of DA/SA were significant prognostic factors of survival for all patients (p = 0.0039, 0.0236, and 0.0385, respectively), whereas the presence of AGGNs was not associated with poor overall survival (p = 0.4809).
CONCLUSION: DA accompanied by AGGNs showed an oncologically less invasive nature compared with SA. Presence of AGGNs is not related to poor prognosis, and is neither indicative of an advanced stage nor a contraindication to surgical resection in patients with clinical stage IA radiological invasive adenocarcinoma.
Copyright © 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Additional ground-glass nodules; Invasive adenocarcinoma; Lung cancer; Survival

Mesh:

Year:  2016        PMID: 26802286     DOI: 10.1016/j.jtho.2016.01.008

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  5 in total

Review 1.  Whack-a-mole strategy for multifocal ground glass opacities of the lung.

Authors:  Kenji Suzuki
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

2.  The effectiveness of mediastinal lymph node evaluation in a patient with ground glass opacity tumor.

Authors:  Youngkyu Moon; Sook Whan Sung; Min Namkoong; Jae Kil Park
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

3.  The prognosis of invasive adenocarcinoma presenting as ground-glass opacity on chest computed tomography after sublobar resection.

Authors:  Youngkyu Moon; Kyo Young Lee; Jae Kil Park
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

4.  [Risk Factors of Nodal Upstaging in Clinical Ia Lung Adenocarcinoma].

Authors:  Yi Qin; Tong Qiu; Yunpeng Xuan; Yandong Zhao; Wenjie Jiao
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2018-06-20

Review 5.  A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation-part 3: systematic review of evidence regarding surgery in compromised patients or specific tumors.

Authors:  Brett C Bade; Justin D Blasberg; Vincent J Mase; Ulas Kumbasar; Andrew X Li; Henry S Park; Roy H Decker; David C Madoff; Whitney S Brandt; Gavitt A Woodard; Frank C Detterbeck
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.